AI Insight
The ISLEND-2 trial evaluated a once-weekly, single-tablet combination of islatravir and lenacapavir compared to daily standard HIV-1 treatment in a phase 3 randomized controlled trial. Results at 48 weeks demonstrated that the once-weekly regimen was non-inferior to daily standard of care in maintaining viral suppression and was generally well tolerated by participants. This represents a potential advancement toward simplified HIV-1 treatment with reduced dosing frequency.
Why it matters
A once-weekly oral HIV treatment regimen could significantly improve medication adherence and quality of life for people living with HIV-1, compared to current daily dosing requirements. This simplified approach may reduce treatment burden and potentially improve long-term health outcomes through better compliance.
Understand the Science
Once-weekly islatravir–lenacapavir showed non-inferior efficacy to the standard of care and was generally well tolerated. Longer-term safety data will provide further valuable insights beyond the week 48 data presented here. Islatravir–lenacapavir has potential to be the first once-weekly complete oral single-tablet regimen for HIV-1 treatment.